Exact Sciences FY2025 EPS Estimate Boosted by William Blair

Key Points

• William Blair has revised its FY2025 earnings per share (EPS) estimate for Exact Sciences from $0.22 to $0.36, while the current consensus estimate stands at ($0.58) per share.
• Various analysts are providing mixed ratings on Exact Sciences, with upgrades and downgrades in price targets, resulting in a consensus rating of "Moderate Buy".
• In the latest quarterly report, Exact Sciences beat earnings expectations significantly, reporting $0.22 EPS against a consensus estimate of (0.02), along with a 16% year-over-year revenue increase.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Investment analysts at William Blair upped their FY2025 earnings per share estimates for shares of Exact Sciences in a research note issued on Wednesday, September 10th. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of $0.36 for the year, up from their previous estimate of $0.22. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences' Q4 2025 earnings at $0.20 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.24. The business had revenue of $811.09 million during the quarter, compared to analysts' expectations of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm's quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.09) earnings per share.

Other equities analysts have also issued research reports about the company. Craig Hallum upped their price objective on Exact Sciences from $65.00 to $85.00 and gave the stock a "buy" rating in a research note on Thursday, September 11th. Wall Street Zen upgraded Exact Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Evercore ISI cut their target price on Exact Sciences from $68.00 to $64.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Barclays cut their target price on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Finally, Piper Sandler reduced their price objective on Exact Sciences from $70.00 to $60.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $68.05.

Exact Sciences Stock Performance

Shares of EXAS traded down $0.27 during trading hours on Monday, hitting $53.32. The stock had a trading volume of 3,098,095 shares, compared to its average volume of 2,630,643. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56. Exact Sciences has a 12 month low of $38.81 and a 12 month high of $72.83. The firm has a market capitalization of $10.09 billion, a PE ratio of -9.82, a PEG ratio of 4.95 and a beta of 1.05. The stock has a fifty day moving average price of $48.85 and a 200 day moving average price of $49.46.

Institutional Trading of Exact Sciences

Large investors have recently modified their holdings of the stock. Bank Pictet & Cie Europe AG increased its holdings in Exact Sciences by 1.2% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 129,024 shares of the medical research company's stock valued at $7,250,000 after buying an additional 1,547 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Exact Sciences by 20.1% during the fourth quarter. Focus Partners Wealth now owns 19,135 shares of the medical research company's stock worth $1,085,000 after buying an additional 3,201 shares during the period. Quantinno Capital Management LP boosted its stake in shares of Exact Sciences by 205.4% during the fourth quarter. Quantinno Capital Management LP now owns 9,991 shares of the medical research company's stock worth $561,000 after buying an additional 6,720 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Exact Sciences in the fourth quarter valued at about $45,000. Finally, Raiffeisen Bank International AG acquired a new stake in Exact Sciences in the fourth quarter valued at about $149,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Insider Buying and Selling

In related news, Director James Edward Doyle sold 1,485 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $42.02, for a total value of $62,399.70. Following the transaction, the director directly owned 59,962 shares in the company, valued at approximately $2,519,603.24. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.